论文部分内容阅读
为评价HA方案治疗初诊慢性髓性白血病 (CML)慢性期患者的临床疗效 ,作者按治疗方案与Sokal危险指数对 94例患者进行分组 ,对比观察单用羟基脲 (0 5～ 3 0g/d)与HA方案治疗慢性期初诊CML的近、远期临床疗效。结果发现 ,HA方案治疗初诊CML慢性期患者的近期疗效较好 ,中、高危组患者获CR率 (77 4% ,2 0 0 % )均优于羟基脲组 (35 0 % ,0 % ) ,但HA方案不能延长CML的慢性期维持时间
To evaluate the clinical efficacy of HA regimen in the treatment of newly diagnosed chronic myelogenous leukemia (CML) chronic phase patients, 94 patients were grouped according to the treatment regimen and the Sokal risk index. The control groups were treated with hydroxyurea alone (0 5 ~ 30 g / d) Short-term and long-term clinical efficacy of HA regimen in treatment of CML with chronic phase. The results showed that the HA regimen was effective in the treatment of newly diagnosed chronic myeloid CML patients, and the CR rates (77 4% and 200%) were higher in the moderate and high risk groups than those in the hydroxyurea group (35 0% and 0%, respectively) However, the HA regimen does not prolong the chronic phase of CML maintenance